Overview

Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome

Status:
Completed

Trial end date:
2003-03-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of fludarabine, carboplatin, and topotecan in treating patients who have relapsed or refractory acute leukemia or advanced myelodysplastic syndrome.

Phase:

Phase 1

Details

Lead Sponsor:

Case Comprehensive Cancer Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Carboplatin
Fludarabine
Fludarabine phosphate
Topotecan
Vidarabine